image: Representatives who will be onsite for the event include Insilico founder and CEO Alex Zhavoronkov, PhD; Chief Business Officer Michelle Chen, PhD; Petrina Kamya, PhD, Global Head of AI Platforms and President of Insilico Medicine Canada; Chief Medical Officer Sujata Rao, MD; Jue Wang, PhD, Head of Business Development, APAC; and Sean Cullen, PhD, Associate Director of Business Development.
Credit: Insilico Medicine
Leadership from clinical stage, generative artificial intelligence (AI)-driven drug discovery company Insilico Medicine (“Insilico”) will attend the 42nd Annual J.P. Morgan Healthcare Conference Jan. 8-11, 2024 in San Francisco.
Representatives who will be onsite for the event include Insilico founder and CEO Alex Zhavoronkov, PhD; Chief Business Officer Michelle Chen, PhD; Petrina Kamya, PhD, Global Head of AI Platforms and President of Insilico Medicine Canada; Chief Medical Officer Sujata Rao, MD; Jue Wang, PhD, Head of Business Development, APAC; and Sean Cullen, PhD, Associate Director of Business Development.
Generative AI is transforming drug discovery and development, and Insilico Medicine is at the forefront of this movement. The Company’s generative AI platform paired with an autonomous AI-powered robotics lab has produced a pipeline of 30+ assets across 29 targets for diseases including cancer, fibrosis, and inflammatory bowel disease (IBD), five of which have advanced into clinical trials. Insilico also has the first AI-discovered and AI-designed drug (for IPF) in Phase II trials; partnerships with pharma companies like Sanofi and Exelixis to advance AI assets in cancer and other indications; and platform licensing agreements with pharma companies like Novo Nordisk and Janssen to drive new discoveries in liver fibrosis and neuroscience.
In December, Insilico announced that its potentially first-in-class AI-designed treatment for IBD, a condition affecting millions worldwide with few therapeutic options, became its fifth AI-designed drug in clinical trials. In September, the Company announced a global licensing agreement with Exelixis for a potentially best in class USP1 inhibitor for BRCA-mutated tumors, for $80m upfront and additional milestone and royalty payments. Insilico presented data at the major cancer conferences in 2023 on the Company's novel, AI-designed cancer assets, including the European Society for Medical Oncology (ESMO) conference, the Society of Immunotherapy of Cancer (SITC) conference, and the San Antonio Breast Cancer Symposium (SABCS). Insilico’s numerous cancer drugs in development include a CDK12/13 inhibitor for wide indications including triple negative breast cancer; an ENPP1 immunotherapy for multiple tumor types; and a KAT6 inhibitor for the treatment of advanced ER+/HER2- breast cancer – the most common subtype of breast cancer.
The Company also recently unveiled substantial updates to its end-to-end platform, including chat functionality, and held a Grand Opening event in November for its AI R&D center in Montreal.
Insilico has raised over $400m in funding to date from notable biotech and tech investors.
About Insilico Medicine
Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases and aging-related diseases.
For media inquiries, please contact media@insilicomedicine.com
For business development, please contact bd@insilicomedicine.com